This study presents an evolving technology in the evaluation and diagnosis of autoimmune diseases. Enzyme-linked immunosorbent assay with specific recombinant target antigens, rather than the less specific immunofluorescence studies that most clinicians rely on to diagnose autoimmune bullous diseases, is used by these investigators to study a unique form of pemphigus. Enzyme-linked immunosorbent assay may be a more cost-effective and specific replacement for immunofluorescence in the future diagnosis of autoimmune disease.
Crosby DL. Future Diagnosis of Autoimmune Diseases. Arch Dermatol. 1999;135(8):947. doi:10.1001/archderm.135.8.947
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: